Non-surgical therapy and radiologic assessment of stage I breast cancer treatment with novel enzyme-targeting radiosensitization: Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, type II (KORTUC II)

Hitomi,Jiro; Kubota,Kei; Ogawa,Yasuhiro; Hamada,Norihiko; Murata,Yoriko; Nishioka,Akihito

doi:10.3892/etm.2010.123

Non-surgical therapy and radiologic assessment of stage I breast cancer treatment with novel enzyme-targeting radiosensitization: Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, type II (KORTUC II)

Authors:
- Jiro Hitomi
- Kei Kubota
- Yasuhiro Ogawa
- Norihiko Hamada
- Yoriko Murata
- Akihito Nishioka
View Affiliations

Affiliations: Department of Radiology, Kochi Medical School, Kochi University, Kochi 783-8505, Japan
Published online on: July 20, 2010 https://doi.org/10.3892/etm.2010.123
Pages: 769-775

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The new enzyme-targeting radiosensitization treatment, kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, type II (KORTUC II), markedly enhances the radiotherapeutic effect of treatment for various types of locally advanced malignant neoplasms. Patients who had declined surgical treatment and systemic chemotherapy, as well as a total of 14 stage I breast cancer patients, were enrolled. A maximum of 6 ml of KORTUC II was injected into tumor tissue twice a week under ultrasonographic guidance, immediately prior to each administration of radiation therapy. The median observation period was 21.6 months with a range of 4-48 months, and the therapy was well tolerated. Contrast-enhanced magnetic resonance imaging and [18F]-fluorodeoxyglucose positron emission computed tomography revealed that all primary breast tumors completely responded, and none of the subjects experienced local recurrence during the observation period. Ultrasonography depicted tumor-like findings in 2/14 cases after therapy. The intratumoral flow signal on color-Doppler sonography was positive in 4/14 cases before therapy, and the signal disappeared from all cases after therapy. The absence of a flow signal after therapy suggested that the tumor-like findings on ultrasonography were from scar tissue. Excellent local control based on accurate radiological evaluation implies that KORTUC II has the potential to replace surgery as a therapeutic option for stage I breast cancer. Precise evaluation by various radiological modalities helped to gage the success of this therapy.

View Figures

View References

1.	Sonoo H and Noguchi S: Results of questionnaire survey on breast cancer surgery in Japan 2004–2006. Breast Cancer. 15:3–4. 2008.
2.	Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, Aguilar M and Marubini E: Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 347:1227–1232. 2002.PubMed/NCBI
3.	Schmitz AC, Gianfelice D, Daniel BL, Mali WP and van den Bosch MA: Image-guided focused ultrasound ablation of breast cancer: current status, challenges, and future directions. Eur Radiol. 18:1431–1441. 2008. View Article : Google Scholar : PubMed/NCBI
4.	Jolesz FA: MRI-guided focused ultrasound surgery. Annu Rev Med. 60:417–430. 2009. View Article : Google Scholar
5.	Manenti G, Bolacchi F, Perretta T, Cossu E, Pistolese CA, Buonomo OC, Bonanno E, Orlandi A and Simonetti G: Small breast cancers: in vivo percutaneous US-guided radiofrequency ablation with dedicated cool-tip radiofrequency system. Radiology. 251:339–346. 2009. View Article : Google Scholar : PubMed/NCBI
6.	Kinoshita T, Iwamoto E, Tsuda H and Seki K: Radiofrequency ablation as local therapy for early breast carcinomas. Breast Cancer. Jan 14–2010.(E-pub ahead of print).
7.	Littrup PJ, Jallad B, Chandiwala-Mody P, D'Agostini M, Adam BA and Bouwman D: Cryotherapy for breast cancer: a feasibility study without excision. J Vasc Interv Radiol. 20:1329–1341. 2009. View Article : Google Scholar : PubMed/NCBI
8.	Ogawa Y, Kubota K, Ue H, Kataoka Y, Tadokoro M, Miyatake K, Tsuzuki K, Yamanishi T, Itoh S, Hitomi J, Hamada N, Kariya S, Fukumoto M, Nishioka A and Inomata T: Phase I study of a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate for topical tumor injection: a new enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II). Int J Oncol. 34:609–618. 2009. View Article : Google Scholar
9.	Ogawa Y, Kubota K, Ue H, et al: Development and clinical application of a new radiosensitizer containing hydrogen peroxide and hyaluronic acid sodium for topical tumor injection – a new enzyme-targeting radiosensitization treatment, KORTUC II (Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas Type II). Strahlenther Onkol. 183:100–101. 2007.PubMed/NCBI
10.	UICC. TNM Classification of Malignant Tumors. 6th edition. Wiley-Liss; New York: pp. 2002
11.	Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B and Senn HJ: 10th St. Gallen conference. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 18:1133–1144. 2007. View Article : Google Scholar : PubMed/NCBI
12.	Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar
13.	Tatsumi M, Cohade C, Mourtzikos KA, Fishman EK and Wahl RL: Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging. 33:254–262. 2006. View Article : Google Scholar : PubMed/NCBI
14.	Halsted WS: The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June, 1889, to January, 1894. Ann Surg. 20:497–555. 1984. View Article : Google Scholar : PubMed/NCBI
15.	Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER and Wolmark N: Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 347:567–575. 2002.PubMed/NCBI
16.	Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH and Wolmark N: Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 347:1233–1241. 2002.PubMed/NCBI
17.	Ogawa Y, Nishioka A, Inomata T, Ohnishi T, Kariya S, Terashima M, Yoshida S, Tohchika N, Tanaka Y and Kumon M: Conservation treatment intensified with an anti-estrogen agent and CAF chemotherapy for stage I and II breast cancer. Oncol Rep. 7:479–484. 2000.PubMed/NCBI
18.	Ogawa Y, Nishioka A, Inomata T, Yokota N, Sasaki T, Terashima M, Yoshida S, Tanaka Y and Tohchika N: Conservation treatment intensified with tamoxifen and CAF chemotherapy without axillary dissection for early breast cancer patients with clinically-negative axillary nodes. Oncol Rep. 6:801–805. 1999.
19.	Ogawa Y, Takahashi T, Kobayashi T, Kariya S, Nishioka A, Mizobuchi H, Noguchi M, Hamasato S, Tani T, Seguchi H, Yoshida S and Sonobe H: Mechanism of apoptotic resistance of human osteosarcoma cell line, HS-Os-1, against irradiation. Int J Mol Med. 12:453–458. 2003.PubMed/NCBI
20.	Ogawa Y, Takahashi T, Kobayashi T, Kariya S, Nishioka A, Ohnishi T, Saibara T, Hamasato S, Tani T, Seguchi H, Yoshida S and Sonobe H: Apoptotic-resistance of the human osteosarcoma cell line HS-Os-1 to irradiation is converted to apoptotic-susceptibility by hydrogen peroxide: a potent role of hydrogen peroxide as a new radiosensitizer. Int J Mol Med. 12:845–850. 2003.PubMed/NCBI
21.	Ogawa Y, Takahashi T, Kobayashi T, Kariya S, Nishioka A, Hamasato S, Moriki T, Seguchi H, Yoshida S and Sonobe H: Immunocytochemical characteristics of human osteosarcoma cell line HS-Os-1: possible implication in apoptotic resistance against irradiation. Int J Mol Med. 14:397–403. 2004.
22.	Ogawa Y, Ue H, Tsuzuki K, Tadokoro M, Miyatake K, Sasaki T, Yokota N, Hamada N, Kariya S, Hitomi J, Nishioka A, Nakajima K, Ikeda M, Sano S and Inomata T: New radiosensitization treatment (KORTUC I) using hydrogen peroxide solution-soaked gauze bolus for unresectable and superficially exposed neoplasms. Oncol Rep. 19:1389–1394. 2008.
23.	Chasin WD, Gross CC, Wang CC and Miller D: Hydrogen peroxide and irradiation of tumors. Arch Otolaryngol. 85:151–155. 1967. View Article : Google Scholar : PubMed/NCBI
24.	Bianchini G, Salgarello G, Mennini T and Lorini G: Intra-arterial infusion of hydrogen peroxide in radiotherapy of malignant tumors. Radiol Med. 55:207–225. 1969.PubMed/NCBI
25.	Coates AS, Keshaviah A, Thurlimann B, et al: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98. J Clin Oncol. 25:486–492. 2007.PubMed/NCBI
26.	Fisher B, Brown AM, Dimitrov NV, et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol. 8:1483–1496. 1990.
27.	Fisher B, Anderson S, Tan-Chiu E, Wolmark N, Wickerham DL, Fisher ER, Dimitrov NV, Atkins JN, Abramson N, Merajver S, Romond EH, Kardinal CG, Shibata HR, Margolese RG and Farrar WB: Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol. 19:931–942. 2001.
28.	Jansen SJ, Otten W and Stiggelbout AM: Review of determinants of patients' preferences for adjuvant therapy in cancer. J Clin Oncol. 22:3181–3190. 2004.
29.	Esserman L, Hylton N, George T and Weidner N: Contrast-enhanced magnetic resonance imaging to assess tumor histopathology and angiogenesis in breast carcinoma. Breast J. 5:13–21. 1999. View Article : Google Scholar : PubMed/NCBI
30.	Esserman L, Hylton N, Yassa L, Barclay J, Frankel S and Sickles E: Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J Clin Oncol. 171:110–119. 1999.PubMed/NCBI
31.	Tsuboi N, Ogawa Y, Inomata T, Yoshida D, Yoshida S, Moriki T and Kumon M: Changes in the findings of dynamic MRI by preoperative CAF chemotherapy for patients with breast cancer of stage II and III: Pathologic correlation. Oncol Rep. 6:727–732. 1999.PubMed/NCBI
32.	Kubota K, Ogawa Y, Nishioka A, Kariya S, Itoh S, Murata Y, Hamada N, Maeda H and Tanaka Y: Diagnostic accuracy of mammography, ultrasonography and magnetic resonance imaging in the detection of intraductal spread of breast cancer following neoadjuvant chemotherapy. Oncol Rep. 17:915–918. 2007.
33.	Nakamura S, Kenjo H, Nishi T, Kazama T, Doi O and Suzuki K: Efficacy of 3D-MR mammography for breast conserving surgery after neoadjuvant chemotherapy. Breast Cancer. 9:15–19. 2002. View Article : Google Scholar : PubMed/NCBI
34.	Leconte I, Feger C, Galant C, Berliere M, Berg BV, D'Hoore W and Maldague B: Mammography and subsequent whole-breast sonography of nonpalpable breast cancers: the importance of radiologic breast density. AJR. 180:1675–1679. 2003. View Article : Google Scholar : PubMed/NCBI
35.	Yang WT, Lam WW, Cheung H, Suen M, King WW and Metreweli C: Sonographic, magnetic resonance imaging, and mammographic assessments of preoperative size of breast cancer. J Ultrasound Med. 16:791–797. 1997.PubMed/NCBI
36.	Berg WA, Gutierrez L, NessAiver MS, Carter WB, Bhargavan M, Lewis RS and Ioffe OB: Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology. 233:830–849. 2004. View Article : Google Scholar : PubMed/NCBI
37.	Adler LP, Crowe JP, Al-Kaisi NH and Sunshine JL: Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology. 187:743–750. 1993.
38.	Avril N, Dose J, Jänicke F, Bense S, Ziegler S, Laubenbacher C, Römer W, Pache H, Herz M, Allgayer B, Nathrath W, Graeff H and Schwaiger M: Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol. 14:1848–1857. 1996.PubMed/NCBI
39.	Hata T, Takahashi H, Watanabe K, Takahashi M, Taguchi K, Itoh T and Todo S: Magnetic resonance imaging for preoperative evaluation of breast cancer: a comparative study with mammography and ultrasonography. J Am Coll Surg. 198:190–197. 2004. View Article : Google Scholar : PubMed/NCBI
40.	Van Goethem M, Schelfout K, Dijckmans L, van Der Auwera C, Weyler J, Verslegers I, Biltjes I and De Schepper A: MR mammography in the pre-operative staging of breast cancer in patients with dense breast tissue: comparison with mammography and ultrasound. Eur Radiol. 14:809–816. 2004.PubMed/NCBI
41.	Gottlober P, Kerscher MJ, Korting HC and Peter RU: Sonographic determination of cutaneous and subcutaneous fibrosis after accidental exposure to ionising radiation in the course of the Chernobyl nuclear power plant accident. Ultrasound Med Biol. 14:9–13. 1997. View Article : Google Scholar
42.	Adams MJ, Lipshultz SE, Schwartz C, Fajardo LF, Coen V and Constine LS: Radiation-associated cardiovascular disease: manifestations and management. Semin Radiat Oncol. 13:346–356. 2003. View Article : Google Scholar : PubMed/NCBI
43.	Jones JP and Leeman S: Ultrasonic tissue characterization. Acta Electronica. 26:3–31. 1984.
44.	Baz E, Madjar H, Reuss C, Vetter M, Hackeloer B and Holz K: The role of enhanced Doppler ultrasound in differentiation of benign vs. malignant scar lesion after breast surgery for malignancy. Ultrasound Obstet Gynecol. 15:377–382. 2000. View Article : Google Scholar : PubMed/NCBI